docetaxel anhydrous has been researched along with Mixed Tumor, Mullerian in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duman, BB; Ercolak, V; Günaldi, M; Kara, IO | 1 |
| Cruickshank, ME; Delaney, E; Hutcheon, AW; McNally, OM; Parkin, DE; Petty, RD | 1 |
1 review(s) available for docetaxel anhydrous and Mixed Tumor, Mullerian
| Article | Year |
|---|---|
Malignant mixed Mullerian tumor of the ovary with two cases and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Disease Progression; Docetaxel; Female; Follow-Up Studies; Humans; Hysterectomy; Mixed Tumor, Mullerian; Neoplasm Staging; Omentum; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Palliative Care; Salpingectomy; Taxoids; Tomography, X-Ray Computed | 2011 |
1 other study(ies) available for docetaxel anhydrous and Mixed Tumor, Mullerian
| Article | Year |
|---|---|
Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers? A population-based study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Docetaxel; Female; Humans; Middle Aged; Mixed Tumor, Mullerian; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Practice Guidelines as Topic; Prospective Studies; Radiotherapy Dosage; Survival Rate; Taxoids | 2003 |